- Home
- SBRA vs KRYS Comparison
SBRA vs KRYS Comparison
Compare SBRA & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBRA
- KRYS
- Stock Information
- Founded
- SBRA 2010
- KRYS 2015
- Country
- SBRA United States
- KRYS United States
- Employees
- SBRA N/A
- KRYS N/A
- Industry
- SBRA Real Estate Investment Trusts
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SBRA Real Estate
- KRYS Health Care
- Exchange
- SBRA Nasdaq
- KRYS Nasdaq
- Market Cap
- SBRA 4.3B
- KRYS 4.5B
- IPO Year
- SBRA N/A
- KRYS 2017
- Fundamental
- Price
- SBRA $17.01
- KRYS $151.55
- Analyst Decision
- SBRA Buy
- KRYS Strong Buy
- Analyst Count
- SBRA 7
- KRYS 7
- Target Price
- SBRA $19.43
- KRYS $206.67
- AVG Volume (30 Days)
- SBRA 1.9M
- KRYS 276.8K
- Earning Date
- SBRA 02-25-2025
- KRYS 02-24-2025
- Dividend Yield
- SBRA 7.05%
- KRYS N/A
- EPS Growth
- SBRA N/A
- KRYS N/A
- EPS
- SBRA 0.41
- KRYS 1.77
- Revenue
- SBRA $682,324,000.00
- KRYS $241,519,000.00
- Revenue This Year
- SBRA N/A
- KRYS $485.81
- Revenue Next Year
- SBRA $7.39
- KRYS $58.65
- P/E Ratio
- SBRA $41.69
- KRYS $85.13
- Revenue Growth
- SBRA 20.53
- KRYS 2722.80
- 52 Week Low
- SBRA $12.83
- KRYS $107.50
- 52 Week High
- SBRA $20.03
- KRYS $219.34
- Technical
- Relative Strength Index (RSI)
- SBRA 49.65
- KRYS 41.79
- Support Level
- SBRA $16.82
- KRYS $141.72
- Resistance Level
- SBRA $17.27
- KRYS $152.94
- Average True Range (ATR)
- SBRA 0.37
- KRYS 5.40
- MACD
- SBRA 0.08
- KRYS 0.08
- Stochastic Oscillator
- SBRA 84.16
- KRYS 49.17
About SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.